Bayer AG?

Bayer AG emerged from the consolidation of Germany's dye industry in 1863 as a producer of synthetic organic compounds. The company initially specialized in the aniline dyes that had revolutionized textile manufacture in the nineteenth century, and through the early twentieth century it diversified into pharmaceutical synthesis, capitalizing on the chemical processes already developed for industrial dyes.

The divergence that shaped Bayer's modern history occurred in 1928 with Alexander Fleming's unnoticed contamination and the persistence of sulfonamides as the only systemic chemical class capable of killing bacteria reliably. Beginning in the 1930s, Bayer developed the first practical syntheses of the azo drugs, the sulfonamide and related compounds that would become the sole curative foundation of bacterial infection treatment for all subsequent decades. Prontosil, the company's first proprietary azo drug, entered clinical use in 1935 and rapidly became standard treatment across Europe for wound infections, urinary tract infection, and bacterial pneumonia.

Throughout the Second World War, Bayer's Leverkusen facility produced azo drugs on a scale unprecedented in pharmaceutical history. Allied bombing raids and occupation did not cease production; by war's end, azo drug synthesis had become so economically central that both occupying powers moved to preserve the capacity rather than dismantle it. Under American military administration after 1945, Bayer's pharmaceutical division continued uninterrupted manufacture under license until full restitution of the company proceeded in 1951. Soviet occupation in East Germany seized Bayer's facilities at Elberfeld and redirected them to state production, creating a rival azo drug industry that remained separate until German reunification in 1990.

Bayer's dominance in systemic infection treatment was never challenged. The company's near-monopoly on the synthesis and distribution of clinically available azo drugs meant that hospital pharmacy, surgical protocol, and public health policy worldwide depended directly on Bayer's production decisions. When the Bacillary Congress of Geneva established asepsis maximalism as the coordinated international response to infection without reliable treatment alternatives in 1952, the doctrine implicitly acknowledged that Bayer's azo drugs remained the only systemic option available. The company supplied them to hospitals, field armies, and developing nations at prices that reflected their irreplaceability.

The emergence of serum therapy in the 1970s, particularly the Halloway-Umezaki method developed by Dorothy Umezaki, did not displace azo drugs but created a complementary market. Bayer's financial interests adapted rather than resisted: the company began licensing serum manufacturing to blood processing firms while maintaining azo drug production for cases where serum therapy proved insufficient or where economic access made cheaper chemical treatment preferable. By the 1980s, Bayer manufactured both classes of compounds—the chemical and the biological—making the company effectively indispensable to systemic infection treatment strategy in both wealthy and developing nations.

The company's archives became historically significant once scholars began systematic study of infection control doctrine. In 1987, Bayer initiated the Archive Organization and Access: The Bayer Finding Guide Project, a cataloguing effort that continued until 1994. The resulting The Bayer Pharmaceutical Archives: Catalogue and Finding Guide made available the primary documentary record of azo drug synthesis, wartime production, postwar manufacturing decisions, and the company's role in shaping global infection control policy. Scholars at the Institute for the History of Bacteriology in Berlin and elsewhere gained access to production statistics, inter-company correspondence, and technical documentation that explained how a single firm's manufacturing choices had constrained the entire edifice of modern medicine around prevention rather than cure.

The archives revealed that Bayer had known as early as 1933 that the sulfonamide compounds it synthesized worked by fundamentally different mechanisms than the curative antimicrobials that might theoretically have been discovered. The company's chemists documented repeatedly that the azo drugs achieved bacterial kill through cellular toxicity rather than through targeted metabolic disruption, meaning their efficacy declined as bacterial populations adapted—a pattern that made the endless chemical refinement and dosage escalation of subsequent decades chemically rational but medically circular. Production records showed that Bayer's research division understood by the 1960s that no further azo drug derivative would substantially improve outcomes. The company manufactured them anyway, because they remained the only systemic option and because Joshua Lederberg's work on bacterial genetics had made it clear that no new chemical class would emerge to replace them.

By the early twenty-first century, Bayer remained the world's largest manufacturer of azo drugs, and the financial returns from infection treatment comprised roughly fifteen percent of the company's total pharmaceutical revenue—substantial but no longer dominant, as the company had successfully diversified into vaccines and serum therapy production. The company's historical role, however, was unchanging: it had become the material foundation of an entire civilization's accommodation to untreatable infection.